MedTrace Logo

Imatinib for Multiple Sclerosis (MS) Relapses

NCT03674099 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2021-08-02

No results posted yet for this study

Summary

To investigate if treatment with Imatinib results in a better outcome than standard care in form of Methylprednisolone(MP) after MS-associated relapses.

Conditions

Interventions

DRUG

Imatinib Mesylate

Tablets 400 mg

DRUG

Methylprednisolone

1 g tablets or infusion

Sponsors & Collaborators

  • The Swedish Research Council

    collaborator OTHER_GOV

  • Tomas Olsson

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2022-12-31
Completion
2023-07-30

Countries

  • Denmark
  • Germany
  • Norway
  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03674099 on ClinicalTrials.gov